Evolent Health (NYSE:EVH) Receives "Buy" Rating from BTIG Research

Key Points

• Evolent Health has received a "buy" rating from BTIG Research, with a target price of $20.00, indicating a potential upside of 128.57% from its current stock price.
• Despite positive analyst ratings, Evolent Health's recent quarterly earningsReports showed a loss of ($0.10) EPS, missing estimates by $0.20, along with a 31.3% decrease in revenue year-over-year.
• Recent institutional investments reflect growing confidence in Evolent Health, with major acquisitions from firms like Durable Capital Partners and Goldman Sachs, highlighting increased interest from hedge funds.

Evolent Health (NYSE:EVH - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at BTIG Research in a report issued on Tuesday,Benzinga reports. They presently have a $20.00 price objective on the technology company's stock. BTIG Research's target price would indicate a potential upside of 128.57% from the stock's current price.

A number of other analysts have also issued reports on the company. Piper Sandler boosted their target price on Evolent Health from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Thursday, August 28th. Stephens reissued an "equal weight" rating and issued a $9.00 target price on shares of Evolent Health in a research report on Wednesday, September 24th. Canaccord Genuity Group reissued a "buy" rating and issued a $16.00 target price on shares of Evolent Health in a research report on Tuesday, September 9th. Truist Financial upped their price objective on Evolent Health from $14.00 to $16.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $13.00 price objective on shares of Evolent Health in a research report on Friday, June 20th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $17.21.

Evolent Health Trading Down 2.2%

EVH opened at $8.75 on Tuesday. Evolent Health has a one year low of $7.06 and a one year high of $29.25. The stock has a market capitalization of $1.03 billion, a PE ratio of -5.43 and a beta of 0.73. The business's 50 day moving average price is $9.31 and its 200 day moving average price is $9.48. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.01.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The technology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.20). Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. The business had revenue of $444.33 million during the quarter, compared to analyst estimates of $459.43 million. During the same quarter in the prior year, the company posted $0.30 earnings per share. The company's revenue was down 31.3% on a year-over-year basis. Evolent Health has set its Q3 2025 guidance at EPS. As a group, equities research analysts expect that Evolent Health will post 0.08 EPS for the current year.

Hedge Funds Weigh In On Evolent Health

A number of institutional investors and hedge funds have recently modified their holdings of EVH. Durable Capital Partners LP acquired a new position in shares of Evolent Health during the second quarter worth $72,326,000. 8 Knots Management LLC acquired a new position in Evolent Health in the second quarter valued at $32,802,000. Goldman Sachs Group Inc. boosted its stake in Evolent Health by 162.2% in the first quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company's stock valued at $26,861,000 after acquiring an additional 1,754,520 shares in the last quarter. Eventide Asset Management LLC boosted its stake in Evolent Health by 33.5% in the first quarter. Eventide Asset Management LLC now owns 6,077,191 shares of the technology company's stock valued at $57,555,000 after acquiring an additional 1,524,885 shares in the last quarter. Finally, Maverick Capital Ltd. acquired a new position in Evolent Health in the second quarter valued at $15,680,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.